Novo Highlights Degludec's Advantage Versus Lantus In Fewer Night-Time Hypoglycemic Events
Phase IIIa data suggest that the benefit of Novo's ultra-long acting insulin Degludec over Sanofi's Lantus is fewer nocturnal hypoglycemic events.
Phase IIIa data suggest that the benefit of Novo's ultra-long acting insulin Degludec over Sanofi's Lantus is fewer nocturnal hypoglycemic events.